Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives Average Recommendation of “Moderate Buy” from Brokerages

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) has earned a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and two have given a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $8.50.

Several research firms have commented on AUTL. Mizuho dropped their target price on shares of Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 31st. Truist Financial raised shares of Autolus Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Zacks Research raised shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, March 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a report on Thursday, April 9th. Finally, Jefferies Financial Group raised shares of Autolus Therapeutics to a “strong-buy” rating in a report on Monday.

Autolus Therapeutics Stock Up 3.2%

Autolus Therapeutics stock opened at $1.60 on Thursday. Autolus Therapeutics has a 52 week low of $1.15 and a 52 week high of $2.70. The company’s 50 day moving average price is $1.50 and its two-hundred day moving average price is $1.52. The stock has a market cap of $425.82 million, a P/E ratio of -1.48 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Friday, March 27th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.07). Autolus Therapeutics had a negative return on equity of 99.05% and a negative net margin of 381.40%.The firm had revenue of $24.29 million for the quarter, compared to the consensus estimate of $23.92 million. On average, equities analysts anticipate that Autolus Therapeutics will post -1.05 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds have recently modified their holdings of the stock. Marex Group plc bought a new stake in shares of Autolus Therapeutics in the 2nd quarter worth approximately $28,000. Independent Advisor Alliance bought a new stake in shares of Autolus Therapeutics in the 4th quarter worth approximately $28,000. SmartHarvest Portfolios LLC bought a new stake in shares of Autolus Therapeutics in the 4th quarter worth approximately $43,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Autolus Therapeutics in the 3rd quarter worth approximately $46,000. Finally, R Squared Ltd raised its holdings in shares of Autolus Therapeutics by 40.1% in the 3rd quarter. R Squared Ltd now owns 30,476 shares of the company’s stock worth $50,000 after purchasing an additional 8,730 shares during the period. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.